Lumiliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug. It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE antibody, for the potential treatment of allergic conditions. Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen. Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007. Results published from the CLL clinical trial failed to meet primary endpoints.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Lumiliximab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Lumiliximab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Lumiliximab. |
| Estrone | Estrone may increase the thrombogenic activities of Lumiliximab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Lumiliximab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Lumiliximab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Lumiliximab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Lumiliximab. |
| Estriol | Estriol may increase the thrombogenic activities of Lumiliximab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Lumiliximab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Lumiliximab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Lumiliximab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Lumiliximab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Lumiliximab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Lumiliximab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Lumiliximab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Lumiliximab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Lumiliximab. |
| Equol | Equol may increase the thrombogenic activities of Lumiliximab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Lumiliximab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Lumiliximab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Lumiliximab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Lumiliximab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Lumiliximab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Lumiliximab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Lumiliximab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Lumiliximab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Lumiliximab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Lumiliximab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Lumiliximab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Lumiliximab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Lumiliximab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Lumiliximab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Lumiliximab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Lumiliximab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Lumiliximab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Lumiliximab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Lumiliximab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Lumiliximab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Lumiliximab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Lumiliximab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Lumiliximab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lumiliximab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Lumiliximab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Lumiliximab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lumiliximab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Lumiliximab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Lumiliximab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Lumiliximab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Lumiliximab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Lumiliximab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Lumiliximab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Lumiliximab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Lumiliximab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Lumiliximab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Lumiliximab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Lumiliximab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Lumiliximab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Lumiliximab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Lumiliximab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Lumiliximab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Lumiliximab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Lumiliximab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Lumiliximab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Lumiliximab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Lumiliximab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Lumiliximab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Lumiliximab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Lumiliximab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Lumiliximab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Lumiliximab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Lumiliximab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Lumiliximab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Lumiliximab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Lumiliximab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Lumiliximab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Lumiliximab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Lumiliximab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Lumiliximab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Lumiliximab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Lumiliximab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Lumiliximab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Lumiliximab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Lumiliximab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Lumiliximab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Lumiliximab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Lumiliximab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Lumiliximab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Lumiliximab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Lumiliximab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Lumiliximab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Lumiliximab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Lumiliximab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Lumiliximab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Lumiliximab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Lumiliximab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Lumiliximab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Lumiliximab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Lumiliximab. |
| Canakinumab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Canakinumab. |